Status: Recruiting
Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.
Participants needed: 40
Trial details
Phase: Phase 2Age: 16-20Biological sex: AllType: InterventionalSponsor: Justin RyderUpdated: Jan 21, 2026Locations: 1
Eligibility criteria
BMI >30 kg/m2 or >95th BMI-Percentile [+12]
ALT > 250U/L at screening [+33]